3.90

0.00% +0.00

Pre-market: 3.90

Geron Corp. (GERN)

Overview News Price History Option Chain Financials Why GERN Down? Discussions Forecast

Geron Corp. stock is currently priced at $3.90, with a 24-hour trading volume of 5.31M. It has seen a +0.00% increased in the last 24 hours and a +8.94% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.85 pivot point. If it approaches the $3.98 resistance level, significant changes may occur.

Previous Close:

$3.90

Open:

$3.89

24h Volume:

5.31M

Market Cap:

$2.31B

Revenue:

$237.00K

Net Income/Loss:

$-184.13M

P/E Ratio:

-11.47

EPS:

-0.34

Net Cash Flow:

$-168.57M

1W Performance:

+0.52%

1M Performance:

+8.94%

6M Performance:

+108.56%

1Y Performance:

+30.43%

1D Range:

$3.82

$3.93

52W Range:

$1.64

$4.30

Geron Corp. Stock (GERN) Company Profile

Name

Geron Corp.

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

650-473-7700

Address

149 Commonwealth Drive, Suite 2070, Menlo Park, CA

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

GERN's Discussions on Twitter

Geron Corp. Stock (GERN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-12-23	Upgrade	Goldman	Neutral → Buy
Mar-28-23	Initiated	Goldman	Neutral
Oct-28-22	Initiated	Wedbush	Outperform
Jul-28-22	Resumed	B. Riley Securities	Buy
Nov-02-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Resumed	B. Riley Securities	Buy
Aug-03-20	Initiated	Stifel	Buy
Nov-19-19	Resumed	B. Riley FBR	Buy
Sep-03-19	Initiated	H.C. Wainwright	Buy
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight
Apr-09-19	Upgrade	Needham	Hold → Buy
Jan-31-19	Upgrade	B. Riley FBR	Neutral → Buy
Oct-02-18	Downgrade	B. Riley FBR	Buy → Neutral
Jul-05-18	Initiated	B. Riley FBR, Inc.	Buy
Sep-13-16	Reiterated	FBR & Co.	Outperform
Sep-13-16	Reiterated	FBR Capital	Outperform
Dec-07-15	Reiterated	Piper Jaffray	Overweight
Apr-21-15	Initiated	Oppenheimer	Outperform
Jun-12-14	Upgrade	MLV & Co	Hold → Buy
Mar-12-14	Downgrade	MLV & Co	Buy → Hold
Dec-10-13	Reiterated	MLV & Co	Buy
Dec-10-13	Upgrade	Needham	Hold → Buy
Nov-08-13	Reiterated	MLV & Co	Buy
Oct-16-13	Initiated	MLV & Co	Buy
Aug-30-12	Initiated	Stifel Nicolaus	Buy
Jun-28-12	Initiated	Needham	Hold

View All

Geron Corp. Stock (GERN) Latest News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Business Wire

New York State Common Retirement Fund Boosts Stake in Geron Co. (NASDAQ:GERN) - Defense World

Defense World

Russell Investments Group Ltd. Buys 204765 Shares of Geron Co. (NASDAQ:GERN) - Defense World

Defense World

Geron Corp. Stock (GERN) Financials Data

Geron Corp. (GERN) Revenue 2024

GERN reported a revenue (TTM) of $237.00 thousand for the quarter ending December 31, 2023, a -60.23% decline year-over-year.

Geron Corp. (GERN) Net Income 2024

GERN net income (TTM) was -$184.13 million for the quarter ending December 31, 2023, a -29.76% decrease year-over-year.

Geron Corp. (GERN) Cash Flow 2024

GERN recorded a free cash flow (TTM) of -$168.57 million for the quarter ending December 31, 2023, a -31.89% decrease year-over-year.

Geron Corp. (GERN) Earnings per Share 2024

GERN earnings per share (TTM) was -$0.33 for the quarter ending December 31, 2023, a +8.33% growth year-over-year.

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.